Adial Pharmaceuticals, Inc 8-K Filings

Adial Pharmaceuticals, Inc. further adjourned the 2026 Annual Meeting votes on Proposals 3, 4, 5 and 6 because it still had not received Nasdaq’s approval of its Initial Listing Application. The meeting reconvened on October 1, 2026, for those proposals before being adjourned again.

The meeting is scheduled to reconvene October 15, 2026, at 8:30 a.m. Eastern Time, and the polls remain open. Votes on Proposals 1, 2, 7, 8, 9, 10, 11 and 12 had already been held. The record date remains August 17, 2026. Stockholders who submitted proxies on Proposals 3, 4, 5 and 6 need not take further action unless they wish to change their votes.

Adial Pharmaceuticals, Inc. (ADIL) reported results from its 2026 Annual Meeting of Stockholders held on September 17, 2026. Stockholders approved Amendment No. 8 to the 2017 Equity Incentive Plan, a new 2026 Equity Incentive Plan, and a 2026 Employee Stock Purchase Plan, expanding the company’s ability to grant equity-based compensation. They also approved an amendment to the certificate of incorporation increasing authorized common shares from 100,000,000 to 500,000,000, and approved the potential issuance of up to 552,940 shares upon exercise of Series F warrants to comply with Nasdaq Listing Rule 5635(d). An adjournment proposal was approved, and the meeting was partially adjourned with respect to four other proposals tied to Nasdaq approvals; those proposals will be voted when the meeting reconvenes on October 1, 2026.

Adial Pharmaceuticals, Inc. (ADIL) amended its June 11, 2026 Securities Purchase Agreement and Note Exchange Agreements to remove a “Penalty Provision” tied to Milestone Warrants and add lock-up restrictions on certain shares issuable from pre-funded warrants. This change allows the Milestone Warrant rights to be reclassified from a liability to equity.

Pro forma as of June 30, 2026, reclassifying $22.7 million of Milestone warrant rights from liability to additional paid-in capital and converting all 12,930.617 Series A Non-Voting Convertible Preferred shares (previously $38.5 million in temporary equity) into common stock turns stockholders’ equity from a $38.4 million deficit to positive $22.9 million, with common shares increasing from 2,625,890 to 15,556,507.

The company states that these steps are intended to help regain compliance with Nasdaq Capital Market continued listing requirements and satisfy initial listing standards in connection with an anticipated change of control, which depends on stockholder approval of the conversion of the Series A Preferred Stock at the 2026 Annual Meeting.

Adial Pharmaceuticals, Inc. (ADIL) reported granting a stock option as a material inducement for a new employee to join the company. On August 19, 2026, the company granted an option to purchase 307,814 shares of common stock at an exercise price of $5.76 per share, the closing price on the grant date. The option has a ten-year term and will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to continued service. The grant was made outside the company’s equity incentive plans under the employment inducement exception in Nasdaq Listing Rule 5635(c)(4) and relies on an exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D. The option and underlying shares may not be sold in the United States without registration or an applicable exemption.

ADIAL PHARMACEUTICALS, INC. (ADIL) disclosed that on August 18, 2026 it received a Nasdaq notice that its stockholders’ equity, as reported in its June 30, 2026 Form 10-Q, no longer meets the $2,500,000 minimum required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The notice also states the company does not meet the alternative standards of a $35 million market value of listed securities or $500,000 in net income from continued operations in the required periods. The company has 45 days, until October 2, 2026, to submit a compliance plan and may receive up to a 180-day extension if Nasdaq accepts the plan. Adial anticipates seeking stockholder approval at its 2026 Annual Meeting to convert outstanding Series A Non-Voting Convertible Preferred Stock as a potential means to restore stockholders’ equity but cautions that there is no assurance it will regain or maintain compliance or avoid delisting.

Adial Pharmaceuticals, Inc. reported its business update for the quarter ended June 30, 2026, alongside second-quarter 2026 results. The company completed the acquisition of Azora Therapeutics, adding lead program AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor agonist being developed for ulcerative colitis.

Adial also closed the first $32 million tranche, including conversion of $5.5 million of notes, of an up to $64 million private financing from biotechnology-focused institutional investors, which it states will support advancement of AT177 through key development milestones. Following the Azora acquisition, Adial’s strategy shifts toward serious inflammatory diseases, with AT177 in IND-enabling studies and an investigational new drug filing planned for the first half of 2027, a Phase 1a SAD/MAD trial planned for the second half of 2027, and a subsequent Phase 1b proof-of-concept study in ulcerative colitis patients. The company indicates that existing cash and cash equivalents are expected to fund operating expenses into the second half of 2027.

Adial Pharmaceuticals, Inc. outlines anticipated leadership and governance changes tied to its 2026 annual meeting of stockholders. As of August 10, 2026, the company anticipates that, if specified proposals receive stockholder approval at the 2026 Annual Meeting, the employment of current President and Chief Executive Officer Cary Claiborne and current Chief Financial Officer Vinay Shah will be terminated promptly after the meeting. The company expects to appoint Matthew Davidson, currently Chief Development Officer and a director, as the new President and Chief Executive Officer, and to appoint a new Chief Financial Officer. Upon termination and subject to execution of a release, Messrs. Claiborne and Shah would receive severance payments and benefits under their amended and restated employment agreements.

The company also anticipates changes to the size and composition of the Board of Directors following stockholder approval, including resignations of legacy board members and replacement with new directors, although no definitive determinations have been made. The 2026 annual meeting is scheduled for September 17, 2026, and stockholder proposals or director nominations, whether under Rule 14a-8 or otherwise, must be received by August 23, 2026 to be considered timely.

Adial Pharmaceuticals, Inc. filed an amended report to add the historical financial statements of its newly acquired subsidiary Azora Therapeutics, Inc. and unaudited pro forma condensed combined financial information following completion of their June 11, 2026 merger. The amendment includes Azora’s audited financials for 2025 and 2024, unaudited results for the quarter ended March 31, 2026, and combined pro forma statements for 2025 and the first quarter of 2026. Azora is a pre‑revenue biopharmaceutical company focused on autoimmune diseases, with a 2025 net loss of $0.7 million and year‑end cash of $0.3 million, and its auditors highlight substantial doubt about its ability to continue as a going concern. The notes describe the merger consideration and a concurrent PIPE financing under which Adial issued pre‑funded and incentive warrants for gross proceeds of about $26.8 million, with the potential for an additional $26.8 million and the extinguishment of $5.5 million of Azora convertible notes through warrant exchanges.

Adial Pharmaceuticals completed the acquisition of Azora Therapeutics in an all-stock transaction and shifted its focus to Azora’s lead ulcerative colitis program, AT177. Azora holders received 437,474 shares of common stock and 12,930.617 shares of Series A non-voting convertible preferred stock, each convertible into 1,000 common shares after stockholder approval.

Before the related financing and note exchange, former Azora equityholders hold about 86.9% of Adial’s fully diluted common stock, while pre-merger Adial holders retain about 13.1%. Adial also arranged up to $64 million in private placement financing, including approximately $32 million upfront via pre-funded warrants, to fund IND-enabling work and Phase 1 studies for AT177 in ulcerative colitis. The deal includes new governance, leadership appointments, inducement equity awards, amended executive employment terms, and a detailed registration rights framework for future resale of the new securities.

Adial Pharmaceuticals reported its first quarter 2026 results and provided a business update focused on its lead candidate AD04 for Alcohol Use Disorder. The company highlighted evolving U.S. regulatory views suggesting, in some cases, a single adequate and well-controlled trial plus confirmatory evidence may support approval, potentially reducing the need for two full Phase 3 studies.

Adial noted growing support for patient-centered endpoints in Alcohol Use Disorder, such as reductions in heavy drinking and cravings, which align with AD04’s clinical profile and prior ONWARD Phase 3 data showing reduced drinking without major safety concerns. The company also outlined a collaboration framework with Molteni Farmaceutici for a potential European commercialization pathway for AD04, subject to a definitive agreement.

Adial is reinforcing its intellectual property, including an international patent application that, if granted, is expected to protect AD04 through at least 2045. The company plans a new Phase 3 program and broader addiction indications but emphasized that progress depends on obtaining sufficient funding or a strategic partner, and it is actively pursuing financing and strategic alternatives.

Adial Pharmaceuticals, Inc. reported that its Compensation Committee approved new equity compensation for leadership. On April 7, 2026, the committee granted restricted stock awards to the company’s named executive officers and additional awards to certain directors.

Directors Kevin Schuyler and Robertson H. Gilliland each received 9,185 restricted stock awards, and director Kermit Anderson received options to purchase 9,185 shares of common stock at an exercise price of $1.64 per share. These awards vest in full on the earlier of one year from the grant date or a Change of Control as defined in Adial’s 2017 Equity Incentive Plan. The Board also approved a standard Restricted Stock Award Agreement form to govern such grants under that plan.

Adial Pharmaceuticals reported its 2025 fiscal year results and gave a broad business update centered on its lead addiction therapy candidate, AD04. The company highlighted positive pharmacokinetic data from study AD04-103, a productive End-of-Phase 2 FDA meeting, and supportive FDA feedback on its in vitro bridging strategy, all backing plans for a rigorous Phase 3 program.

Adial cited evolving U.S. policy discussions that may allow a single pivotal trial plus confirmatory evidence for approval in some cases, which it believes could lower Phase 3 costs and shorten timelines for AD04. The company also outlined a collaboration framework with Molteni Farmaceutici for exclusive commercialization of AD04 in Europe, with an anticipated definitive agreement including upfront and milestone payments and royalties, and total potential value estimated at nearly $60 million if AD04 successfully launches.

Additional updates included regaining compliance with Nasdaq’s minimum bid price requirement, publication of an international patent application that is expected to extend AD04 protection through at least 2045 once granted, and a six-figure milestone payment from Adovate tied to a Phase 1 asthma trial. Adial describes itself as a clinical-stage company developing genetically targeted treatments for Alcohol Use Disorder and other addictions.

Adial Pharmaceuticals entered a collaboration framework agreement with Molteni Farmaceutici for a proposed exclusive partnership to commercialize AD04 in Europe, while also updating shareholders on a special meeting that could not be convened due to lack of quorum.

The framework, subject to a final definitive agreement, outlines clinical, regulatory, manufacturing, and commercial terms and gives Molteni an exclusivity period to assess a European launch of AD04. A future definitive agreement is expected to include an upfront payment, development and commercial milestones, and tiered royalties ranging from high single digits to low double digits on European AD04 net sales, with total potential milestones and royalties estimated at nearly $60 million if AD04 advances and launches successfully.

Separately, the special meeting of stockholders called to approve the issuance of up to 13,823,512 shares upon exercise of New Warrants under a November 25, 2025 inducement agreement could not be held because a quorum was not present. Under that agreement, Adial must call additional stockholder meetings every 90 days until approval is obtained or the New Warrants are no longer outstanding.

Adial Pharmaceuticals announced that it has regained full compliance with Nasdaq’s minimum bid price requirement. Nasdaq confirmed that for 10 consecutive business days, from February 6 through February 20, 2026, Adial’s common stock closed at $1.00 per share or higher, and the compliance matter is now closed.

The company highlights this as an important milestone as it advances its lead drug candidate AD04 toward a pivotal Phase 3 program for Alcohol Use Disorder and continues advanced strategic partnering discussions to support further development and potential commercialization.

Adial Pharmaceuticals, Inc. is implementing a 1-for-25 reverse stock split of its common stock, reducing outstanding shares from approximately 27.8 million to approximately 1.1 million. The amendment to the Certificate of Incorporation becomes legally effective at 11:59 p.m. Eastern Time on February 5, 2026.

The common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on February 6, 2026, continuing under the symbol “ADIL”, with a new CUSIP of 00688A304. Fractional shares will not be issued; instead, stockholders will receive a cash payment based on the average closing price over the ten trading days before the effective time.

The company states that the primary purpose of the reverse split is to raise the per-share trading price to support continued listing on the Nasdaq Capital Market, which requires a minimum bid price of at least $1.00 per share, while noting there is no assurance the split will achieve this for the required period.

Adial Pharmaceuticals, Inc. reported that on January 5, 2025, board member James W. Newman, Jr. resigned from the company’s Board of Directors, effective immediately. He had been serving as a non-employee director and was also a member of both the Audit Committee and the Compensation Committee.

The company states that Mr. Newman did not report any disagreement with Adial on matters related to its operations, policies, or practices in connection with his resignation. The report is signed on behalf of Adial Pharmaceuticals by President and Chief Executive Officer Cary J. Claiborne.

Adial Pharmaceuticals, Inc. filed a current report to note that it issued a press release containing financial information for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to the report.

The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the federal securities laws and will not be incorporated by reference into other SEC filings. The report is signed on behalf of the company by President and Chief Executive Officer Cary J. Claiborne.

Adial Pharmaceuticals reported FDA feedback supporting its adaptive trial design for AD04 in alcohol use disorder (AUD). The FDA recognized AUD as an unmet need and agreed with core protocol elements including biomarker-defined positive and negative cohorts, inclusion criteria targeting moderate-to-severe AUD, trial duration, interim analysis sample size, and safety monitoring. The agency confirmed the primary efficacy endpoint of zero heavy drinking days during months 5 and 6 of the efficacy observation period and advised pre-specifying key secondary endpoints for labeling consideration. FDA also reviewed the planned interim analyses, the Statistical Analysis Plan, and the Data Monitoring Committee structure, stressing alignment among protocol, simulation report, and SAP to ensure proper alpha control and reduce post-trial analysis risk.

Adial Pharmaceuticals received a Nasdaq notice granting an additional 180 days, until March 2, 2026, to regain compliance with the $1.00 minimum bid price required for continued listing on the Nasdaq Capital Market.

The company must have its stock close at or above $1.00 per share for at least ten consecutive business days, and it has told Nasdaq it may use a reverse stock split, if needed, to cure the deficiency, completing any split at least ten business days before the deadline. If Adial fails to regain compliance by March 2, 2026, Nasdaq staff may move to delist the shares, though the company would have the right to appeal to a hearings panel.

Adial Pharmaceuticals, Inc. furnished an update on its financial results by issuing a press release that includes financial information for the fiscal quarter ended June 30, 2025. The company submitted this press release as Exhibit 99.1 to a current report on Form 8-K.

The company states that the press release and related Item 2.02 information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the federal securities laws and will not automatically be incorporated by reference into other SEC filings.

Adial Pharmaceuticals, Inc. (ADIL) reported the completion of a best-efforts public offering on 18 June 2025 that generated gross proceeds of approximately $3.6 million. The transaction combined newly issued common shares, pre-funded warrants and two new warrant series, materially increasing the company’s potential fully-diluted share count.

Key terms of the offering

• 5,341,200 new common shares and 5,758,800 pre-funded warrants were sold. Each share or pre-funded warrant unit was paired with one Series D and one Series E warrant.
• Pricing: $0.3251 per common share unit; $0.3241 per pre-funded unit.
• Aggregate securities created: up to 11,100,000 Series D warrant shares (exercise price $0.35; 5-year life) and 8,325,000 Series E warrant shares (exercise price $0.35; 18-month life).
• Pre-funded warrants have a de minimis $0.001 exercise price and no expiration; all warrants include customary anti-dilution and cashless-exercise features and a 4.99%/9.99% ownership cap.
• The securities were registered on Form S-1 (File No. 333-287826) declared effective 16 June 2025.

Use of proceeds: The company intends to deploy the net funds for working capital and general corporate purposes.

Placement & lock-ups: A.G.P./Alliance Global Partners acted as exclusive placement agent, earning 7.0 % of gross proceeds (less a 3.5 % credit on tail-list investors) plus a 1.0 % management fee and up to $75,000 in expense reimbursement. The purchase and placement agreements restrict additional equity issuances for 30 days (general) and 60 days (ATM/variable rate), with limited exceptions.

Warrant amendments: Concurrently, the exercise price on existing Series B-1 (2,482,270 shares) and Series C-1 (4,025,000 shares) warrants was reduced to $0.35. Expirations were extended to 17 Jun 2030 (B-1) and 17 Dec 2026 (C-1), subject to future shareholder approval obligations.

Investor impact

• The raise strengthens near-term liquidity but is modest relative to the potential issuance of up to 30 million additional shares, implying significant dilution.
• Common warrant exercise is conditional on shareholder approval to be secured within 120 days; failure to obtain approval could delay additional dilution or cash inflow.
• The repricing and term extension of prior warrants increases the likelihood of further share issuance at $0.35.

Overall, the 8-K details substantial low-priced equity and warrant issuance that improves cash resources but materially increases future dilution risk.